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OBJECTIVE—Somatostatin (SST) is secreted by islet -cells
and by extraislet neuroendocrine cells. SST receptors have been
identiﬁed on - and -cells, and exogenous SST inhibits insulin
and glucagon secretion, consistent with a role for SST in regu-
lating - and -cell function. However, the speciﬁc intraislet
function of -cell SST remains uncertain. We have used Sst
/
mice to investigate the role of -cell SST in the regulation of
insulin and glucagon secretion in vitro and in vivo.
RESEARCH DESIGN AND METHODS—Islet morphology was
assessed by histological analysis. Hormone levels were measured
by radioimmunoassay in control and Sst
/ mice in vivo and
from isolated islets in vitro.
RESULTS—Islet size and organization did not differ between
Sst
/ and control islets, nor did islet glucagon or insulin
content. Sst
/ mice showed enhanced insulin and glucagon
secretory responses in vivo. In vitro stimulus-induced insulin and
glucagon secretion was enhanced from perifused Sst
/ islets
compared with control islets and was inhibited by exogenous
SST in Sst
/ but not control islets. No difference in the
switch-off rate of glucose-stimulated insulin secretion was ob-
served between genotypes, but the cholinergic agonist carba-
mylcholine enhanced glucose-induced insulin secretion to a
lesser extent in Sst
/ islets compared with controls. Glucose
suppressed glucagon secretion from control but not Sst
/ islets.
CONCLUSIONS—We suggest that -cell SST exerts a tonic
inhibitory inﬂuence on insulin and glucagon secretion, which
may facilitate the islet response to cholinergic activation. In
addition, -cell SST is implicated in the nutrient-induced suppres-
sion of glucagon secretion. Diabetes 58:403–411, 2009
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slets of Langerhans are heterogeneous cell aggre-
gates containing -, -, -, and PP cells, which
secrete insulin, glucagon, somatostatin (SST), and
pancreatic polypeptide, respectively. The different
cell types within the islet are affected by changes in the
extracellular glucose concentration. Thus, elevations in
circulating glucose stimulate insulin secretion from islet
-cells and inhibit glucagon secretion from -cells as part
of the reciprocal regulation of blood glucose by insulin and
glucagon. SST secretion from islet -cells is also stimu-
lated by increased extracellular glucose, although the
threshold concentration for -cells to respond to glucose is
lower than that for -cells (1), and the ionic events in
stimulus-response coupling differ between - and -cells
(2).
Rodent islets have a deﬁned architecture with a -cell
core surrounded by a mantle of non–-cells (3), whereas
human islets do not show such pronounced anatomical
subdivisions (4). The anatomical organization of islets is
important for their correct functioning, and there is much
evidence to suggest that cell-cell interactions within islets
are crucial for normal function (5–9). Interactions be-
tween islet -cells have been investigated extensively, and
we have previously demonstrated the importance of ho-
motypic -cell interactions in the regulation of insulin
secretion (10,11). Similarly, there have been numerous
studies of possible interactions between - and -cells
within islets (9,12–15). Less attention has been paid to the
possible intraislet roles of -cell–derived SST. -Cells
comprise 5–10% of the islet endocrine cells (3), but the
peptide hormone SST is also synthesized and secreted by
neuroendocrine cells in the central nervous system and
the gastrointestinal system, and the latter is the major
contributor to circulating SST (16,17). SST often acts as an
inhibitory regulator of endocrine systems, for example, as
a hypothalamic factor to suppress growth hormone secre-
tion from the anterior pituitary (18), or as a local inhibitor
of the release of gastrointestinal peptide hormones (19).
SST receptors (SSTR1–5) have been identiﬁed on both -
and -cells (20), and exogenously administered SST or
SST analogs inhibit glucose-induced insulin secretion and
arginine-induced glucagon secretion both in vitro and in
vivo (21–24). In addition, studies using SSTR-deﬁcient
mice (SSTR1, -2, or -5) revealed changes in both basal and
stimulated insulin secretion (21,25,26). However, studies
using SSTR knockout models are difﬁcult to interpret
because mouse islets express all ﬁve SSTRs (20) and
reduced expression of one receptor subtype may be
compensated for by the overexpression of another. There-
fore, although current data are consistent with a negative
regulatory role for SST in islet secretory function, it is
unclear whether this effect can be ascribed to circulating
SST or to locally released -cell SST.
The study of -cell function within islets is complicated
by the possibility of multiple heterotypic interactions
between islet cell types in experiments using intact pri-
mary islets. Studies of islet SST have also been hampered
by the lack of selective and potent SST receptor antago-
nists. To investigate the role of locally released -cell SST,
we have therefore used a mouse model in which disrup-
tion of the SST gene produced a SST-deﬁcient phenotype
(27). Our results suggest that locally released -cell SST
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DIABETES, VOL. 58, FEBRUARY 2009 403exerts a tonic inhibitory inﬂuence on insulin and glucagon
secretion and that this inhibitory effect of -cell SST may
be involved in facilitating the insulin secretory response to
cholinergic activation and the nutrient-induced suppres-
sion of glucagon secretion.
RESEARCH DESIGN AND METHODS
Sst
/ mice on a C57BL/6J background were generated as described previ-
ously (27) and subsequently rederived onto a CBA/Ca  C57BL/10 F1
background by backcrossing to CBA/Ca  C57BL/10 F1 mice for 10 genera-
tions, followed by intercrossing to generate Sst
/ mice on a mixed CBA/Ca 
C57BL/10 F1 background. Age-matched CBA/Ca  C57BL/10 F1 mice served
as controls.
Islet isolation. Islets from 8- to 12-week-old female Sst
/ or control mice
were isolated by collagenase digestion (1 mg/ml; type XI; Sigma, St. Louis,
MO) and separated from exocrine pancreatic tissue on a histopaque gradient
(Sigma). Islets were incubated overnight at 37°C (5% CO2) in RPMI 1640 (10%
FBS, 2% glutamine, 100 units/ml penicillin/0.1 mg/ml streptomycin, and 11
mmol/l glucose) before experiments.
PCR. RNA was extracted from islets using an RNAeasy kit (Qiagen, Sussex,
U.K.). Reverse transcription to cDNA and RT-PCR ampliﬁcation were per-
formed as described previously (28) using the primer sequences shown in
Table 1. All reactions were carried out for 40 cycles. Products were separated
on agarose gels and visualized by staining with 0.5 g/ml ethidium bromide.
Immunohistochemistry and morphometric analysis. An estimate of islet
size and number per mm
2 pancreas was obtained by morphometric analysis of
ﬁxed pancreatic sections labeled for insulin by immunohistochemistry. The
entire parafﬁn-embedded pancreas from each animal was cut into 5-m
sections onto microscope slides and sections selected for staining and
morphometry. Sections were systematically sampled throughout the entire
pancreas to give 20 sections per animal for analysis. Sections were dewaxed,
hydrated, and labeled with a mouse monoclonal antibody to insulin (Sigma),
and positive cells were visualized with a peroxidase-conjugated secondary
antibody to mouse IgG and diaminobenzidine as substrate. Sections were
counterstained with hematoxylin, and digital images of sections were used for
image analysis. Diameters of islets and area of insulin- and glucagon-labeled
cells within islets on each section were measured with the aid of image
analysis software (ImageJ). Numbers of islets, deﬁned as clusters of ﬁve or
more -cells on the section, were determined relative to pancreatic area. For
assessment of the organization of - and -cells within the islets, 10 sections
per animal were labeled with mouse monoclonal antibodies to glucagon
(Sigma) or insulin, respectively, and positive cells were visualized as de-
scribed above.
Insulin and glucagon secretion
In vivo studies. Eight- to 12-week-old female mice were fasted overnight
before the experiments. The animals were anesthetized with sodium pento-
barbital (667 g  100 l
1  10 g
1 mouse i.p.), and a cannula was inserted into
the jugular vein. Glucose (0.5 g/kg) or arginine (0.25 g/kg) was injected, and
blood samples were withdrawn at time points indicated in the legend of Fig.
2. For insulin clearance tests, nonfasted mice were injected intravenously with
0.4 unit/kg insulin, and blood samples were withdrawn as indicated in the
legend of Fig. 2. Samples were centrifuged, and blood glucose was measured
in the plasma using a glucose analyzer (Analox).
In vitro studies. For measuring the dynamics of insulin or glucagon release,
islets were transferred into chambers of a temperature-controlled multichan-
nel perifusion system as described previously (29) and perifused for 70 min at
37°C with a bicarbonate-buffered physiological salt solution (30) containing 2
mmol/l glucose. The tissue was subsequently perifused (0.5 ml/min) with salt
solution containing agents of interest, and fractions were collected at 2-min
intervals or as indicated on graphs. For static secretion experiments, islets
were preincubated for 60 min in buffer containing 2 mmol/l glucose (or 1
mmol/l for SST secretion experiments), after which batches of 15 islets were
incubated for 60 min in 0.5-ml salt solution containing agents of interest. The
SST 14 isoform (SST-14; St. Helens, Bachem, U.K.) was used as an exogenous
source of SST. For assessment of islet hormone content, islets were pelleted
by centrifugation, washed with PBS, lysed in acidiﬁed ethanol, and sonicated.
Hormone immunoassays. Insulin and glucagon content of incubation me-
dium and islet extracts and insulin content of plasma samples were assessed
by radioimmunoassay (RIA) using in-house assays, as described previously
(31,32). SST and plasma glucagon levels were measured using commercially
available RIA kits (SST: Euro-Diagnostica, Malmo ¨, Sweden; Glucagon: Linco,
St. Charles, MO).
Data analysis. Data are expressed as means  SE and analyzed statistically
using Student’s t test, one- or two-way ANOVA, and Bonferroni’s multiple
comparisons test, as appropriate. For statistical analysis of dynamic hormone
release, data were expressed as the area under the curve after subtraction of
basal secretion values. Differences between treatments were considered
signiﬁcant at P  0.05.
RESULTS
Phenotypic characterization of control and Sst
/
mice, pancreata, and islets. There were no signiﬁcant
differences in growth or body weight in the Sst
/ female
mice versus controls at the ages studied (20  0.5 vs.
20.9  0.5 g, Sst
/ vs. control, n 	 6, P 
 0.2), nor did the
Sst
/ animals show any overt behavioral dissimilarities
or any differences in resting normoglycemia (8.1  0.28 vs.
7.4  0.14 mmol/l glucose, Sst
/ vs. control, n 	 36–41,
P 
 0.2). Insulin tolerance tests showed no differences in
sensitivity or maximal glucose suppression between fe-
male Sst
/ and controls (Fig. 2C; P 
 0.2). Histological
analysis of pancreatic sections found no signiﬁcant differ-
ences in the size distribution of islets in control and Sst
/
pancreata (control, 97.2  3.5 m; Sst
/, 95.6  4.7, n 	
88–217 islets from three animals per group, P 
 0.2) nor in
the number of islets per mm
2 pancreas (control, 0.739 
0.054 islets/mm
2; Sst
/, 0.617  0.064, n 	 3, P 
 0.2).
Furthermore, the ratio of -t o-cell area (control, 0.267 
0.031; Sst
/, 0.282  0.048, n 	 32–34 sections from three
TABLE 1
SST and SSTR1–5 mRNA expression in control and Sst
/ islets
Primer sequence Product (bp) T
ann(C°) mRNA expression
Sst
/ Sst
/
SST F: ccagactccgtcagtttc 124 56 
R: gctccagggcatcattct
SSTR1 F: ttttgtcatctgctggatgc 167 59.9 
R: ggaaagagcgcttgaagttg
SSTR2 F: acgccaagatgaagaccatc 197 55.7 
R: catgaccgtcaagcagaaga
SSTR3 F: tggtgatctacgtggtcctg 163 59.9 
R: agacggcacatgagagatcc
SSTR4 F: tgctaactgctggcatgaag 154 59.9 
R: ttcagcactgacaccaggag
SSTR5 F: cgacttcgtacagcaatcca 213 58 
R: ctcacagaggttggctcaca
SST mRNA was detected by RT-PCR in control but not in Sst
/ mouse islet extracts, conﬁrming the absence of endogenous -cell SST in
Sst
/ mice. SSTR1–5 mRNAs were identiﬁed in both control and Sst
/ islet extracts. F, forward primer, R, reverse primer.
HORMONE SECRETION FROM Sst
/ MOUSE ISLETS
404 DIABETES, VOL. 58, FEBRUARY 2009animals per group, P 
 0.2) and the cellular organization
of - and -cells within the islet were similar in islets from
control and Sst
/ animals. Thus, in both control and
Sst
/ islets, glucagon-positive -cells were located pri-
marily at the periphery, whereas -cells formed a central
core (Fig. 1).
In vivo islet hormone secretion from control and
Sst
/ mice. To assess the importance of SST in regulat-
ing islet hormone release, we initially examined the in vivo
islet hormone secretory responses in female mice in the
presence or absence of endogenous SST. No differences
were detected in basal plasma levels of insulin and gluca-
gon (Fig. 2; P 
 0.2), but plasma levels of both hormones
were signiﬁcantly elevated in Sst
/ mice when compared
with control mice after intravenous administration of
glucose (0.5 g/kg; Fig. 2A; P  0.01) or arginine (0.25 g/kg;
Fig. 2B; P  0.001), respectively. In separate experiments,
plasma insulin levels were also enhanced in male Sst
/
mice compared with control animals in response to glu-
cose (data not shown).
In vitro hormone secretion from control and Sst
/
islets. To determine whether the enhanced secretory
responses in Sst
/ mice could be attributable to a speciﬁc
lack of -cell SST rather than a global absence of circulat-
ing SST, in vitro secretion studies were carried out using
islets isolated from female Sst
/ and control mice, as
shown in Fig. 3. There was no signiﬁcant difference
between the basal rate of hormone secretion from control
and Sst
/ islets (Fig. 3A–C; P 
 0.2), whereas stimulus-
induced insulin and glucagon release was signiﬁcantly
enhanced in the Sst
/ islets (Fig. 3A–D). Thus, Sst
/
islets showed approximately twofold greater insulin and
glucagon secretory responses to elevations in glucose and
arginine, respectively, compared with control islets (glu-
cose, P  0.05; arginine, P  0.001). The augmented
secretory responses did not reﬂect increased islet hor-
mone content because the content of both insulin (control,
66.0  8.6 ng/islet; Sst
/, 50.0  7.2, n 	 6, P 
 0.1) and
glucagon (control, 3.5  0.5 ng/islet; Sst
/, 2.8  0.5, n 	
7, P 
 0.1) did not differ signiﬁcantly between genotypes.
As a consequence, the differences in secretory responses
between genotypes were observed whether secretion was
expressed as a rate (Fig. 3A) or as a percentage of total
insulin content (Fig. 3B). Enhanced insulin secretion from
Sst
/ islets was not dependent on a nutrient stimulus,
because similar effects were observed when secretion was
initiated by the sulfonylurea tolbutamide, which bypasses
glucose transport and metabolism and stimulates insulin
secretion by direct effects on plasma membrane ATP-
sensitive K
 channels (Fig. 3D; Sst
/ vs. control; P 
0.01). Thus, the ﬁrst-phase of tolbutamide-induced insu-
lin secretion was improved in Sst
/ islets compared
with control islets. Parallel experiments using control
islets demonstrated that -cells also responded to the
secretagogues, which stimulate insulin and glucagon
Control, insulin Control, glucagon
Sst-/-, insulin Sst-/-, glucagon
FIG. 1. Intraislet organization of - and -cells from control and Sst
/
islets. Consecutive sections of control (A and B)o rSst
/ (C and D)
mouse islets were stained for insulin (A and C) or glucagon (B and D),
respectively, and are representative of sections from three different
animals. (Please see http://dx.doi.org/10.2337/db08-0792 for a high-
quality digital representation of this ﬁgure.)
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FIG. 2. Insulin and glucagon secretion in vivo. A: Plasma insulin levels
in Sst
/ mice and control mice 0, 2, 5, and 15 min after an intravenous
glucose challenge (0.5 g/kg). Points show means  SE for four to six
separate animals. B: Plasma glucagon levels in Sst
/ mice and control
mice 0, 2, and 5 min after injection of intravenous arginine (0.25 g/kg).
Points show means  SE for 5 and 14 separate animals (Sst
/ and
control, respectively). C: Plasma glucose levels in Sst
/ mice and
control mice 0, 15, 30, 45, and 60 min after injection of intravenous
insulin (0.4 units/kg). Points show means  SE for ﬁve separate
animals.
A.C. HAUGE-EVANS AND ASSOCIATES
DIABETES, VOL. 58, FEBRUARY 2009 405secretion, as shown in Fig. 3E. Accordingly, glucose,
tolbutamide, and arginine all caused signiﬁcant in-
creases in SST secretion from islets in vitro by 4-, 4.5-,
and 2-fold, respectively.
RT-PCR measurements conﬁrmed the expression of
mRNAs for SST receptor subtypes 1–5 in both control and
Sst
/ islets (Table 1). Exogenous SST (1 mol/l) had no
signiﬁcant effect in vitro on stimulus-dependent insulin
(Fig. 4A) or glucagon (Fig. 4B) secretion from control
islets (P 
 0.2) but exerted a marked inhibition of secre-
tion of both hormones from Sst
/ islets (Fig. 4A and B;
P  0.001).
Insulin secretion from control and Sst
/ islets after
removal of glucose stimulus. To investigate whether
-cell SST facilitates the rapid cessation of insulin secre-
tion when normoglycemia is achieved, we measured the
rate of insulin secretion from perifused islets in vitro. As
shown in Fig. 5, the rate at which insulin secretion
declined to basal levels on removal of glucose (20
mmol/l) was not decreased in Sst
/ islets compared
with control islets (Fig. 5A). Similarly, no differences in
the switch-off rate of insulin secretion were detected
when insulin secretion was expressed as a percentage of
stimulated response, to take into account the different
magnitude of glucose-induced stimulation in the two
genotypes (Fig. 5B).
Parasympathetic stimulation of insulin secretion
from control and Sst
/ islets. Figure 3E shows that
glucose, arginine, and tolbutamide all stimulated SST
secretion from -cells, consistent with enhanced insulin
and glucagon release in response to these stimuli in the
absence of -cell SST. However, as shown in Fig. 6A and B,
activation of islet cholinergic receptors had opposite ef-
fects on insulin and SST secretion, inducing the expected
enhancement of glucose-induced insulin secretion (P 
0.001; Fig. 6A) while causing a concomitant inhibition of
glucose-induced SST secretion (P  0.01; Fig. 6B). These
observations are consistent with the effects of carbamyl-
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experiments. In B, the same results are expressed as a per-
centage of total insulin content. C: Arginine-induced (20
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of the symbols. D: Insulin secretory responses to the sulfonyl-
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typical of three separate experiments. *P < 0.05, **P < 0.01 vs.
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406 DIABETES, VOL. 58, FEBRUARY 2009choline (CCh), an acetylcholine analog, on insulin secre-
tion from control and Sst
/ islets, as shown in Fig. 6C.
Thus, both control and Sst
/ islets showed an ampliﬁca-
tion of glucose-induced insulin secretion in response to
CCh (Fig. 6C) with no detectable differences in the rate of
onset of CCh-induced insulin secretion. However, the
extra magnitude of the secretory response of Sst
/ islets
to CCh was less than that of control islets, when compared
with the glucose-induced secretory response alone (Fig.
6D).
Lack of glucose-induced suppression of glucagon
secretion in Sst
/ islets. Our studies using Sst
/ islets
also revealed an important role for -cell SST in the
inhibition of glucagon secretion in response to increases in
plasma glucose. Thus, glucose-induced suppression of
glucagon secretion in vitro was not detected in Sst
/
islets (Fig. 7), although it was present in control islets at
both high (Fig. 7A and C) and intermediate (Fig. 7C and D)
glucose concentrations in both static and dynamic secre-
tion experiments. Figure 7B shows the release of insulin in
response to glucose in the same experiment as Fig. 7A.
DISCUSSION
Although SST is acknowledged as an inhibitor of insulin
and glucagon secretion, the physiological relevance of
-cell SST remains unknown. Our in vivo data showing
that the global absence of SST in Sst
/ mice resulted in
increased glucagon and insulin secretion in response to
nutrient stimuli conﬁrmed the importance of SST as a
negative regulator of islet - and -cell function but did not
identify -cells as the source of that SST. However, in our
in vitro studies, the isolated islets were removed from
neural, neuroendocrine, and gastrointestinal sources of
SST, and this enabled us to focus on the functional
consequences of an absence of islet SST. Overall, the lack
of any signiﬁcant differences in islet size, hormone con-
tent, or morphology between Sst
/ and control islets
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tion are most likely due to the absence of SST. Conse-
quently, our in vitro studies demonstrated that the lack of
locally released -cell SST had a profound effect on both
insulin and glucagon secretion, leading to enhanced levels
of stimulus-induced release of both hormones from Sst
/
islets compared with control islets without affecting basal
levels of hormone secretion. Thus, although we cannot
rule out an effect of circulating SST of neuroendocrine
and/or gastrointestinal origin on islet function in vivo, our
in vivo and in vitro studies are consistent with an impor-
tant role for islet SST in the regulation of - and -cell
secretory function. Our direct measurements of SST secre-
tion in vitro also conﬁrmed previous reports that some
insulin and/or glucagon secretagogues, including glucose,
arginine, and tolbutamide, also stimulate the secretion of
SST from -cells (1,33,34). Taken together, our data are
consistent with a model in which SST released from islet
-cells exerts direct, tonic inhibitory effects on glucagon
and insulin secretion from neighboring - and -cells.
Under resting conditions, the quiescent -cells exert little
or no inﬂuence on the neighboring - and -cells, and no
difference is observed between control and Sst
/ islets
with regard to basal secretion nor in the basal levels of
plasma insulin and glucagon between control and Sst
/
mice. However, exposure of islets to glucose or sulfonyl-
ureas activates both -cells and -cells (1,34), which
initiates an insulin secretory response and simultaneously
causes the local release of SST to limit that response.
Similarly, the stimulation of glucagon secretion by argi-
nine is accompanied by both the activation of -cells (33)
and the intraislet release of SST to limit the -cell secre-
tory response. In this way, both in vitro and in vivo results
are consistent with -cell SST exerting an inhibitory para-
crine inﬂuence on islet - and -cells. The route through
which -cell SST reaches - and -cells is uncertain; early
reports on islet blood ﬂow do not support a vascular route
from -cells to - and -cells (35,36), although other data
do imply a direct vascular route from -t o-cells (37).
Alternatively, SST delivery may be mediated by diffusion
via interstitial compartments (38,39) independent of islet
vasculature. An extensive exploration of the mechanism of
action of islet SST was beyond the scope of this study, but
it is of interest that the ﬁrst phase of insulin release was
enhanced in Sst
/ islets, perhaps suggesting a direct or
indirect effect via the ATP-sensitive K
 channels.
The proposed model of paracrine regulation of islet
function by -cell SST is further supported by our obser-
vations that exogenous SST had no signiﬁcant effect in
vitro on stimulus-dependent insulin or glucagon secretion
from control islets but exerted a marked inhibition of
secretion of both hormones from Sst
/ islets. The lack of
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control islets is consistent with a tonic inhibition by
endogenous -cell SST of islet hormone secretion that
cannot be further repressed by the provision of exogenous
SST. In contrast, the absence of this inhibitory input by
endogenous SST in Sst
/ islets reveals the ability of
exogenous SST to inhibit both insulin and glucagon secre-
tion. An experimental model in which -cell SST prevents
further inhibition by exogenous SST would account for the
reported (22) and anecdotal variability of the effects of
SST on islet hormone secretion in studies using isolated
islets, because the inhibition of hormone secretion by
exogenous SST will be inversely related to the content of
endogenous SST in islet -cells, which are easily lost or
damaged during islet isolation because of their location on
the periphery of the islets, particularly in rodents (40).
The intraislet inhibitory input from -cells is likely to be
involved in ﬁne-tuning - and -cell responses to external
signals: The regulation of homeostatic responses through
a balance between excitatory and inhibitory inputs has
many parallels in physiology and would enable the precise
degree of control required for the endocrine regulation of
plasma glucose within strict limits. We considered ﬁrst
whether -cell SST was used to ensure the rapid cessation
of insulin secretion on achieving normoglycemia (41).
However, our in vitro measurements demonstrated that
the rate of decline of insulin secretion on removal of
glucose was not decreased in Sst
/ islets compared with
control islets, suggesting that -cell SST does not regulate
the termination of insulin secretory responses to glucose.
Although many insulin secretagogues also stimulate SST
release from -cells, we found that the receptor-operated
cholinergic agonist CCh enhanced glucose-induced insulin
secretion but caused a marked inhibition of glucose-
induced SST secretion from control islets, as has been
suggested by some previous studies (42,43). The proposed
model of paracrine regulation of insulin secretion by -cell
SST would therefore predict that activation of islet cho-
linergic receptors in the presence of stimulatory concen-
trations of glucose enhances insulin secretion both by
direct stimulatory effects on -cells and by relieving the
inhibitory -cell input as a consequence of the CCh-
mediated inhibition of glucose-induced SST secretion. In
this model, the effect of cholinergic activation to enhance
a maximum glucose-induced insulin secretory response
will be reduced in the absence of SST because the tonic
inhibitory effect of SST on glucose-induced insulin secre-
tion will be absent and will therefore not be alleviated by
CCh. Our in vitro studies using Sst
/ islets concur with
this prediction. Thus, both control and Sst
/ islets
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DIABETES, VOL. 58, FEBRUARY 2009 409showed an ampliﬁcation of glucose-induced insulin secre-
tion in response to CCh to achieve similar maximum rates
of secretion. However, the extent of the CCh-induced
component of the secretory response in Sst
/ islets was
much less than that of control islets when compared with
their maximum responses to glucose alone. The overall
effect of the presence of -cell SST was therefore to
enhance the amplitude of the CCh-induced component of
the secretory response. We propose that one physiological
function of the tonic inhibitory input of -cell SST on islet
-cells is to ensure that a relatively transient stimulatory
input via parasympathetic activation results in large
changes in the overall mass of insulin secreted for the
duration of the cholinergic activation.
Finally, our in vitro experiments using Sst
/ islets
revealed a further role for -cell SST in the inhibition of
glucagon secretion in response to increases in extracellu-
lar glucose. Various mechanisms have been proposed for
the inhibitory effects of glucose on -cell secretory func-
tion, including direct effects of glucose on -cells (1,44) or
paracrine inhibitory effects of -cell secretory products
such as insulin (14), Zn
2 (13), and -aminobutyric acid
(45). In our experiments using Sst
/ islets, glucose-
induced suppression of glucagon secretion was not de-
tected, although it was observed in control islets over a
range of glucose concentrations, suggesting that glucose-
induced SST release is a major contributor to the inhibi-
tory effects of glucose on islet -cells. Consistent with this,
it has been reported recently that the concentration de-
pendency of glucose-induced inhibition of glucagon secre-
tion correlates closely to that for the stimulation of SST
secretion but is dissociated from that for -cell activation
(1). Our results therefore suggest an important role for
-cell SST in the regulation of glucagon secretion by
glucose but do not rule out the involvement of other
regulatory mechanisms.
In summary, our studies using Sst
/ mice support
important intraislet paracrine roles for -cell–derived SST
in the regulation of islet hormone secretion. Intraislet SST
exerts tonic inhibitory effects on stimulus-induced insulin
and glucagon secretion, which may be important in regu-
lating responses to receptor-operated stimuli, such as
cholinergic agonists. Our studies also suggest that -cell
SST also plays a signiﬁcant role in the suppression of
glucagon secretion by glucose. These observations high-
light the importance of -cells in the normal function of the
endocrine pancreas and suggest that -cell dysfunction in
diabetes (46) may have important consequences for hor-
mone secretion from islet - and -cells.
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